<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894825</url>
  </required_header>
  <id_info>
    <org_study_id>M108-Ⅰ</org_study_id>
    <nct_id>NCT04894825</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China</brief_title>
  <official_title>A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FutureGen Biopharmaceutical (Beijing) Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FutureGen Biopharmaceutical (Beijing) Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The&#xD;
      aim of this phase I study is to establish safety and Tolerability of different Dosage regimen&#xD;
      in patients With Advanced Unresectable Solid Tumors in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From enrollment until 28+7 days after the last dose</time_frame>
    <description>defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>21 days</time_frame>
    <description>MTD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration of M108</measure>
    <time_frame>From enrollment until 28 days after the last dose</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of M108</measure>
    <time_frame>From enrollment until 28 days after the last dose</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of M108</measure>
    <time_frame>From enrollment until 28 days after the last dose</time_frame>
    <description>T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of M108</measure>
    <time_frame>From enrollment until 28 days after the last dose</time_frame>
    <description>Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From first dose to disease progression , death or end of study，an average of 1 year</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From first dose to disease progression , death or end of study，an average of 1 year</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Advanced Unresectable Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.&#xD;
Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design.&#xD;
The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the effective dose has been determined, 1~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M108</intervention_name>
    <description>Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)</description>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M108</intervention_name>
    <description>IV infusion Q3W. (21-day cycles)</description>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <other_name>Chemotherapy.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Advanced Unresectable solid tumors proven by histology&#xD;
&#xD;
          3. At least 1 measurable site of the disease according RECIST 1.1 criteria&#xD;
&#xD;
          4. ECOG performance status (PS) 0-1&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
          6. Age ≥ 18 years and ≤75 years&#xD;
&#xD;
          7. Adequate haematological function; absolute neutrophil count ≥1.5 x 109/L; white blood&#xD;
             cell count ≥3.0 x 109/L; platelets ≥100 x 109/L; haemoglobin ≥9 g/dL.&#xD;
&#xD;
          8. Adequate coagulation function; international normalized ratio ( INR) ≤ 1.5 x upper&#xD;
             limit of normal (ULN), or activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.&#xD;
&#xD;
          9. Adequate hepatic function; bilirubin ≤1.5 x ULN, aspartate aminotransferase (AST), and&#xD;
             alanine aminotransferase (ALT) ≤2.5 x ULN.&#xD;
&#xD;
         10. Adequate renal function; creatinine ≤1.5 x ULN, or reatinine clearance rate ≥60&#xD;
             mL/minute calculated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous received or planned to be vaccinated with 2019-nCoV vaccine or other vaccines&#xD;
             within 3 months prior to the start of study treatment or during the study or within 3&#xD;
             months after the end of the study;&#xD;
&#xD;
          2. Previous radiotherapy within 4 weeks prior to the start of study treatment. (if&#xD;
             palliative radiotherapy was given to bone metastatic side peripherally and the patient&#xD;
             recovered from acute toxicity was allowed).&#xD;
&#xD;
          3. Previous anti-tumor therapy within 4 weeks prior to the start of study treatment.&#xD;
&#xD;
          4. Previous major operation within 8 weeks prior to the start of study treatment.&#xD;
&#xD;
          5. Prior severe allergic reaction or intolerance to a monoclonal antibody, including&#xD;
             humanised or chimeric antibodies.&#xD;
&#xD;
          6. Symptomatic cerebral metastases.&#xD;
&#xD;
          7. Uncontrolled or severe illness.&#xD;
&#xD;
          8. Known human immunodeficiency virus infection or known symptomatic hepatitis&#xD;
&#xD;
          9. Other clinically significant disease which may have adversely affected the safe&#xD;
             delivery of treatment within this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinghua Hou</last_name>
    <phone>021-31185838</phone>
    <email>houxh_mj@futuregenbiopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaochun Yang</last_name>
    <phone>021-31185838</phone>
    <email>yangxc_mj@futuregenbiopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, PhD</last_name>
      <phone>010-88196358</phone>
      <email>doctorshenlin@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

